Therapeutic Application of Genetically Engineered Ribosome-Inactivating Toxin Proteins for Cancer
- 1 December 2021
- journal article
- Published by SciRes Literature LLC in Journal of Biomedical Research & Environmental Sciences
- Vol. 2 (12), 1216-1228
- https://doi.org/10.37871/jbres1375
Abstract
Recently, Ribosome-Inactivating Proteins (RIPs) as a class of anticancer medicines have garnered considerable attention due to their novel anticancer mechanism. Although the medications are small, RIPs utilize the Large-Size Effect (LSE) to block the efflux procedure that are regulated through Drug Resistance Transporters (DRTs), and protect host cells from drug transfection. There are many significant challenges for their therapeutic applications that seriously restrict their usefulness, particularly their strategy towards tumor cells. The primary objective of this review is to emphasize Trichosanthin (TCS) along with Gelonin (Gel) and additional types of RIPs, particularly scorpion venom-derived RIPs, to demonstrate that they should be grappling through what kinds of bio-barriers to overcome in cancer therapeutic science. Next, we will emphasize the latest state-of-the-art in providing cancer treatment RIPs.Keywords
This publication has 89 references indexed in Scilit:
- Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini reviewCancer Chemotherapy and Pharmacology, 2013
- Vascular Permeability and Drug Delivery in CancersFrontiers in Oncology, 2013
- Acidic extracellular microenvironment and cancerCancer Cell International, 2013
- Trichosanthin Inhibits Breast Cancer Cell Proliferation in Both Cell Lines and Nude Mice by Promotion of ApoptosisPLOS ONE, 2012
- Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier functionProceedings of the National Academy of Sciences of the United States of America, 2012
- High Interstitial Fluid Pressure Is Associated with Tumor-Line Specific Vascular Abnormalities in Human Melanoma XenograftsPLOS ONE, 2012
- The crystal structure of a voltage-gated sodium channelNature, 2011
- Chemical Re-engineering of Chlorotoxin Improves Bioconjugation Properties for Tumor Imaging and Targeted TherapyJournal of Medicinal Chemistry, 2011
- Pathways and mechanisms of endocytic recyclingNature Reviews Molecular Cell Biology, 2009
- Blood–Brain Barrier Transport of Therapeutics via Receptor-MediationPharmaceutical Research, 2007